Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Alto Neuroscience (ANRO) Equity Average (2023 - 2026)

Alto Neuroscience has reported Equity Average over the past 4 years, most recently at $197.3 million for Q1 2026.

  • Quarterly results put Equity Average at $197.3 million for Q1 2026, up 35.78% from a year ago — trailing twelve months through Mar 2026 was $197.3 million (up 35.78% YoY), and the annual figure for FY2025 was $151.3 million, up 279.26%.
  • Equity Average reached $197.3 million in Q1 2026 per ANRO's latest filing, up from $131.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $197.3 million in Q1 2026 and bottomed at -$66.4 million in Q4 2023.
  • Median Equity Average over the past 4 years was $131.3 million (2025), compared with a mean of $94.0 million.
  • The largest annual shift saw Equity Average surged 481.19% in 2024 before it crashed 31.86% in 2025.
  • Over 4 years, Equity Average stood at -$66.4 million in 2023, then skyrocketed by 338.39% to $158.3 million in 2024, then fell by 17.0% to $131.3 million in 2025, then surged by 50.18% to $197.3 million in 2026.
  • Business Quant data shows Equity Average for ANRO at $197.3 million in Q1 2026, $131.3 million in Q4 2025, and $117.5 million in Q3 2025.